Glenmark initiates Favipiravir Phase 3 clinical study for COVID-19
Category: #health  By Saipriya Iyer  Date: 2020-05-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Glenmark initiates Favipiravir Phase 3 clinical study for COVID-19

Glenmark Pharmaceuticals Limited has reportedly begun the process for Favipiravir’s phase 3 clinical trials among the patients with coronavirus disease across India to be able to test both efficacy and safety of the antiviral drug.

As per the executives of Glenmark who are familiar with ongoing development, the company shall be recruiting patients from various hospitals across the red zones of states like Gujarat, Delhi and Maharashtra wherein the cases for coronavirus are too high. Once the drug gets commercialized if its approved, it shall be marketed with the brand name called ‘FabiFlu’ across India.

Glenmark plans enrolling patients from a minimum of 10 private and government hospitals from all over the country to conduct the trials. The results for the same is anticipated to come out by July or August.

Glenmark is the first company to start with Favipiravir Phase 3 clinical trials for patients suffering from coronavirus in India. Favipiravir is mainly a generic version of Fujifilm Toyama Chemical Co. Ltd.’s Avigan, the former being a Fujifilm Corporation’s subsidiary. The clinical trials have already began and it will have participants from over renowned private and government hospitals from India that shall get enrolled for the study. It is estimated that the study shall be completed by July or August in 2020.

Favipiravir is essentially an antiviral med that is mostly used in the treatment of influenza in Japan. Glenmark is manufacturing a more generic version of Avigan and has developed an active pharmaceutical ingredient (API) as well as formulations of the product via in-house research & development team.

Shinzo Abe, Prime Minister of Japan has pushed the advantages of Avigan and has created a major inventory of the same, that was originally manufactured as a cure for Ebola, regardless of the lack of evidence concerning the drug works for treating and curing any disease found in human.

 

Source Credit- https://www.hindustantimes.com/india-news/glenmark-begins-phase-3-clinical-trials-of-favipiravir/story-8ykNqhJWZhc2pWnAQZBWVN.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

AdaptHealth enters definitive deals to acquire Solara & ActivStyle
AdaptHealth enters definitive deals to acquire Solara & ActivStyle
By Saipriya Iyer

AdaptHealth Corp. has recently entered two separate definitive agreements for the acquisition of Solara Medical Supplies, LLC and ActivStyle, Inc. AdaptHealth is a leading home medical supplies, equipment, and other re...

Ambani’s JioMart unveils a new website to deliver orders across India
Ambani’s JioMart unveils a new website to deliver orders across India
By Saipriya Iyer

Jio Platforms, the top telecom operator along with Jio Retail, which is the top retail chain has recently unveiled JioMart’s new website and has begun taking orders in a large amount from tier 1, tier 2 and metro c...

Omada enters $30M acquisition deal with digital health company Physera
Omada enters $30M acquisition deal with digital health company Physera
By Saipriya Iyer

Omada Health, which has raised nearly $57 million in funding, has reportedly acquired a digital health company, Physera. It provides remote physical therapy to its customers.

The co...